8-K: Envoy Medical Secures $4M Upfront, $12M Potential in Equity Offering

Envoy Medical Inc. announced a registered direct offering of common stock and a concurrent private placement of warrants, raising $4 million upfront with a potential for an additional $12 million.

Summary

• Envoy Medical Inc. entered into a Securities Purchase Agreement on October 7, 2025, for a registered direct offering and a concurrent private placement.
• The registered direct offering involves the sale of 3,007,524 shares of Class A common stock at a purchase price of $1.33 per share.
• A concurrent private placement includes the issuance of unregistered warrants to purchase up to 9,022,572 shares of Class A common stock.
• These private warrants have an exercise price of $1.33 per share, are immediately exercisable, and expire twenty-four months following the effective date of the resale registration statement for the underlying shares.
• The offering is expected to close on October 9, 2025.
• Gross proceeds from the registered direct offering are anticipated to be approximately $4.0 million.
• An additional potential $12.0 million in gross proceeds could be realized if all private warrants are fully exercised in cash.
• H.C. Wainwright & Co., LLC is acting as the exclusive placement agent, receiving a 7.5% cash fee and a 1.0% management fee on gross proceeds from the registered offering, plus reimbursements up to $85,950.
• The placement agent will also receive warrants to purchase up to 225,564 shares of common stock at an exercise price of $1.6625 per share, expiring on the earlier of two years from the effective date or October 7, 2030.
• Further compensation for the placement agent includes a 7.5% cash fee and a 1.0% management fee on the gross exercise price of any private warrants exercised, plus additional placement agent warrants for 7.5% of the exercised shares.
• The net proceeds are intended for working capital and other general corporate purposes.

Sentiment

Score: 4

Explanation: While the capital raise provides necessary funding, the significant dilution, relatively low share price, and substantial fees to the placement agent indicate a challenging financing environment for the company. The potential future capital from warrant exercise is positive but uncertain.

Positives

• Secured $4.0 million in gross proceeds upfront, providing immediate capital for working capital and general corporate purposes.
• Potential to raise an additional $12.0 million in gross proceeds if all private warrants are exercised, offering future funding flexibility.
• The offering was priced 'at-the-market' under Nasdaq rules, suggesting the pricing was aligned with current market conditions.
• The company is taking steps to ensure liquidity for investors by agreeing to file a registration statement for the resale of warrant shares.

Negatives

• Significant dilution for existing shareholders due to the issuance of 3,007,524 new shares and warrants for up to 9,022,572 shares, plus additional placement agent warrants.
• The exercise price of the private warrants ($1.33) and placement agent warrants ($1.6625) is relatively low, potentially indicating a lower valuation or a need to incentivize investors.
• Substantial fees and expenses associated with the offering, including 8.5% in cash fees to the placement agent on gross proceeds, plus reimbursements and additional warrants.
• No guarantee that the private warrants will be exercised, meaning the potential $12 million in additional proceeds is not assured.
• Restrictions on the company's ability to issue new equity or enter into variable rate transactions for specified periods (15 days and 1 year, respectively), limiting financial flexibility.

Risks

• Potential delays in expected litigation and appeals of jury verdicts, which could affect the company's ability to collect damage awards or result in reduced awards.
• Risks related to the company's plans for its intellectual property, including strategies for monetizing, licensing, expanding, and defending its patent portfolio.
• Risks associated with patent infringement litigation initiated by the company, or by others against the company, as well as the costs and unpredictability of any such litigation.
• Risks associated with the company's product sales, including the market and demand for products sold by the company and its ability to successfully develop and launch new products that are attractive to the market.
• The success of product, joint development and licensing partnerships.
• The competitive landscape of the company's industry.
• General economic, political and market conditions.
• Warrants may expire and never be exercised, meaning the potential additional gross proceeds of $12 million may not be realized.
• Hedging activities by purchasers could negatively impact the market price of the company's publicly-traded securities.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and other general corporate purposes. It also plans to file a registration statement on Form S-1 for the resale of the warrant shares within 30 days and use commercially reasonable efforts to make it effective within 90 days, keeping it effective until purchasers no longer own warrants or warrant shares. The company acknowledges that the potential $12 million from warrant exercise is not assured and warrants may expire unexercised.

Management Comments

• Envoy Medical Inc. (NASDAQ: COCH), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 3,007,524 shares of its Class A common stock at a purchase price of $1.33 per share, in a registered direct offering priced at-the-market under Nasdaq rules.
• Envoy Medical intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Industry Context

This capital raise provides Envoy Medical with additional funding to support its operations and strategic initiatives in the hearing health sector, which is characterized by ongoing innovation in fully implanted hearing solutions. The use of a registered direct offering and private placement of warrants is a common strategy for smaller, growth-oriented companies in the medical device industry to raise capital, balancing immediate funding needs with future potential. The 'at-the-market' pricing suggests a reliance on current market valuation, which can be a challenge for companies in specialized, high-R&D fields.

Corporate Governance

Legal Proceedings

• Risks include potential delays in expected litigation and appeals of jury verdicts, which could affect the company's ability to collect damage awards or result in reduced awards.
• Risks associated with patent infringement litigation initiated by the company, or by others against the company, as well as the costs and unpredictability of any such litigation.

Stakeholder Impact

• Shareholders: Significant dilution from the issuance of new shares and warrants. Potential for future dilution if warrants are exercised. Share price could be negatively impacted by the offering's terms and potential hedging activities by purchasers.
• Investors (Purchasers): Acquire shares and warrants at a specific price, with potential for future gains if the stock price increases. Benefit from certain protections against future dilutive financing and stock splits.
• Company (Envoy Medical): Receives immediate capital for operations and general corporate purposes, with potential for additional funding from warrant exercises. Incurs substantial costs and restrictions on future financing activities.
• Placement Agent (H.C. Wainwright & Co., LLC): Earns significant fees and warrants for facilitating the offering.

Next Steps

• Closing of the offering on or about October 9, 2025.
• Company to file a registration statement on Form S-1 for the resale of the Warrant Shares within 30 calendar days of the Securities Purchase Agreement date (October 7, 2025).
• Company to use commercially reasonable efforts to cause the S-1 registration statement to become effective within 90 calendar days following the closing of the offering.
• Company to keep the resale registration statement effective until no Purchaser owns any Private Warrants or Warrant Shares.
• Company to maintain listing of Common Stock on its Trading Market and apply to list all newly issued shares and warrant shares.
• Purchasers may exercise Private Warrants, potentially providing additional capital to the company.

Key Dates

Recommendation

While the capital raise provides necessary funding for working capital and general corporate purposes, the significant dilution from the issuance of new shares and warrants, coupled with the relatively low offering price and substantial placement agent fees, presents immediate headwinds for existing shareholders. The potential for future capital from warrant exercises is positive but uncertain. Investors should hold to monitor the company's execution of its strategic initiatives and the impact of this financing on its financial health and stock performance, especially given the risks related to litigation and product development in the hearing health sector.

Keywords

Envoy Medical, COCH, Registered Direct Offering, Private Placement, Warrants, Equity Raise, Common Stock, SEC Filing, Capital Raise, Financial Health, Hearing Health, Medical Devices, Investment, Dilution, H.C. Wainwright & Co.